Incyte’s monoclonal antibody Monjuvi reduced certain follicular lymphoma patients’ risk of progression, relapse or death by 57% compared to placebo, the company announced Monday. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.